newsfilter
← Latest News
GlobeNewswire·

Medexus Pharmaceuticals Reports Financial and Operational Results for the Three- and Six-Month Periods Ending September 30, 2021

Achieved $17.9 million revenue driven by continued strength of Rupall™ Positioned for revenue growth along with expected recovery of IXINITY® sales Commercially launched Trecondyv® (treosulfan) in Canada Available liquidity of $9.6 million